Kamada

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Kamada reports robust earnings, eyes global expansion and clinical milestones

Kamada's strong financial performance, strategic acquisitions, and global expansion efforts position the company for continued growth and market success.
While facing challenges in maintaining growth momentum and operational efficiency, Kamada's focus on innovation and market expansion presents significant opportunities for future development.
Investors should monitor Kamada's progress in clinical trials, product diversification, and international market penetration to assess the company's long-term growth potential and market positioning.

Kamada secures $60M investment, targets 35% revenue growth in 2023

Kamada's Q1 2023 performance showed revenue and EBITDA growth, supported by strategic investments and regulatory approvals. While facing rising expenses and financial challenges, the company aims for significant revenue growth in 2023 through market expansion and trial acceleration.

Kamada (KMDA) reports strong Q2 earnings and secures $60M investment

Kamada (KMDA) delivered robust financial results in Q2 2023, with significant revenue growth and positive EBITDA performance.
The company's strategic investments, diverse product pipeline, and regulatory progress underscore its potential for future growth and market expansion.
Stable cash position, operational efficiency, and ongoing clinical advancements position Kamada favorably in the biopharmaceutical industry.
Overall, Kamada's Q2 performance and future outlook reflect a promising trajectory for sustained growth and value creation for shareholders.

Kamada reports robust Q3 earnings, eyes growth through clinical trials

Kamada's Q3 2023 earnings call highlighted strong financial performance, debt-free status, and strategic initiatives for future growth. The company's focus on product development, clinical trials, and board expertise positions it well for continued success and profitability.

Kamada reports robust 2023 earnings, eyes growth through strategic initiatives

Kamada's strong financial performance in 2023 and positive outlook for 2024 underscore the company's growth trajectory and market positioning.
While facing challenges such as rising operating expenses, Kamada's focus on innovation, market expansion, and strategic partnerships presents opportunities for sustained growth.
Maintaining a robust balance sheet and advancing key clinical trials reflect Kamada's commitment to financial stability, product development, and long-term value creation.

Kamada doubles profitability in Q1 2024, eyes revenue growth

Kamada delivered robust financial performance in Q1 2024, with doubled profitability and revenue growth driven by key products. The company's strategic initiatives, including product launches and clinical trial progress, position it well for future success. While facing cost pressures, Kamada's strong cash position and focus on innovation present opportunities for sustained growth.

Kamada excels in Q2, eyes global expansion and clinical milestones

Kamada's strong financial performance in Q2 2024 and the first half of the year, coupled with reaffirmed full-year guidance, reflect a positive growth trajectory and financial stability.
The company's strategic focus on organic growth, M&A activities, and clinical trials positions it well to capitalize on market opportunities and drive future revenue expansion.
While challenges such as dividend policy, regulatory timelines, and market competition exist, Kamada's proactive approach to business development and global partnerships underscores its commitment to sustained growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REHOVOT, Israel, Feb.  26, 2020  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019, with the U.S. Securities and Exchange Commission (the “SEC”).

Kamada Files Annual Report for the Year Ended December 31, 2019

Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities Execution of Securities Purchase Agreement with FIMI Opportunity Fund, an Existing Strategic Investor, to Support Kamada’s Growth Plans and Execution of Strategic Business Opportunities

Kamada Announces $25 Million Private Placement with FIMI Opportunity Fund

Kamada (KMDA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Kamada (KMDA) Could Beat Earnings Estimates Again

REHOVOT, Israel, Dec.  16, 2019  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has been randomized in Europe into its pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The study is being led by Jan Stolk, M.D., Department of Pulmonology, Member of European Reference Network LUNG, Leiden University Medical Center, The Netherlands.   

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

REHOVOT, Israel, Dec.  09, 2019  (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a U.S. Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product.  Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.

Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product

REHOVOT, Israel, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the Israeli Ministry of Health (IMOH). Kamada leverages its expertise and presence in the Israeli market to distribute, in Israel, more than 20 products that are manufactured by third parties.

Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

Kamada Ltd. (KMDA) CEO Amir London on Q3 2019 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of 66.67% and 14.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Beats Q3 Earnings and Revenue Estimates

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kamada (KMDA) to Report Q3 Results: Wall Street Expects Earnings Growth

The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB ®  in 2017

Kamada and Kedrion Biopharma Announce Publication of Results from the Registration Study of KEDRAB® (Rabies Immune Globulin [Human]) in Human Vaccines & Immunotherapeutics Medical Journal

REHOVOT, Israel, Sept.  24, 2019  (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019, in New York City. The presentation will take place on Friday, October 4, at 10:05 am ET. 

Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates

Kamada (KMDA) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Great Lakes Dredge & Dock

Herc Hlds

Malibu Boats

SYNNEX

SunCoke Energy

Let's consider six stocks with a remarkable net profit margin to build a successful portfolio.

Tap These 6 Stocks That Flaunt Impressive Net Profit Margin

Kamada Ltd. (KMDA) CEO Amir London on Q1 2019 Results - Earnings Call Transcript

Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.

Kamada (KMDA) Stock Moves -1.05%: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.

Kamada (KMDA) Gains As Market Dips: What You Should Know

Is  (KMDA) Outperforming Other Medical Stocks This Year?

Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

In the latest trading session, Kamada (KMDA) closed at $5.95, marking a -1.16% move from the previous day.

Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know

Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

In the latest trading session, Kamada (KMDA) closed at $5.76, marking a +0.17% move from the previous day.

Kamada (KMDA) Gains But Lags Market: What You Should Know

Kamada (KMDA) closed at $5.79 in the latest trading session, marking no change from the prior day.

News for Kamada Stock (KMDA)